Differences in Angiotensin Convertase Enzyme (ACE) Activity and Expression May Contribute to Shorter Event Free Period After Coronary Artery Bypass Graft Surgery

Andrea Daragó, Miklós Fagyas, Ivetta M. Siket, Andrea Facskó, Zita Megyesi, Judit Kalász, Zoltán Galajda, Tamás Szerafin, J. Hársfalvi, I. Édes, Z. Papp, Attila Tóth, József Szentmiklósi

Research output: Contribution to journalArticle

Abstract

Aims: The goal of this study was to investigate the importance of the vascular angiotensin convertase enzyme (ACE) in coronary artery bypass graft surgery (CABG) patients. Methods: Vascular tissue (distal saphenous vein [n= 163] and/or radial artery [n= 120] segments) and blood samples were collected from CABG patients (n= 81). We studied (i) the potency of angiotensin I (AngI) and angiotensin II (AngII) to evoke vascular contractions; (ii) vascular and plasma ACE concentrations; and (iii) ACE genotype of the patients enrolled. Results: The ratio of the potencies (EC 50) of AngII and AngI was significantly lower in radial artery compared to the saphenous vein (0.17 ± 0.03 nM and 0.51 ± 0.14 nM, respectively, P= 0.003), suggesting a 3-fold more effective AngI conversion in saphenous vein samples. Angiotensin constrictions were inhibited with telmisartan and captopril in both saphenous veins and radial arteries. Vascular ACE expression was significantly higher in saphenous vein compared to radial artery (9.7 ± 1.0 ng/mg and 5.3 ± 0.7 ng/mg, respectively, P= 0.01). Serum but no tissue ACE concentration was determined by ACE insertion/deletion polymorphism. Accordingly, no relation was found between serum and tissue ACE expression. Conclusion: ACE-inhibitor therapy targeting tissue located ACE may be beneficial to patients with saphenous vein grafts after CABG surgery.

Original languageEnglish
Pages (from-to)136-144
Number of pages9
JournalCardiovascular Therapeutics
Volume30
Issue number3
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Angiotensins
Coronary Artery Bypass
Transplants
Saphenous Vein
Enzymes
Radial Artery
Blood Vessels
Angiotensin I
Angiotensin II
Enzyme Therapy
Captopril
Enzyme Inhibitors
Serum
Constriction
Genotype

Keywords

  • Angiotensin convertase enzyme
  • Interventional cardiology
  • Ischemic heart disease
  • Saphenous vein graft
  • Vascular biology

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Differences in Angiotensin Convertase Enzyme (ACE) Activity and Expression May Contribute to Shorter Event Free Period After Coronary Artery Bypass Graft Surgery. / Daragó, Andrea; Fagyas, Miklós; Siket, Ivetta M.; Facskó, Andrea; Megyesi, Zita; Kalász, Judit; Galajda, Zoltán; Szerafin, Tamás; Hársfalvi, J.; Édes, I.; Papp, Z.; Tóth, Attila; Szentmiklósi, József.

In: Cardiovascular Therapeutics, Vol. 30, No. 3, 06.2012, p. 136-144.

Research output: Contribution to journalArticle

Daragó, Andrea ; Fagyas, Miklós ; Siket, Ivetta M. ; Facskó, Andrea ; Megyesi, Zita ; Kalász, Judit ; Galajda, Zoltán ; Szerafin, Tamás ; Hársfalvi, J. ; Édes, I. ; Papp, Z. ; Tóth, Attila ; Szentmiklósi, József. / Differences in Angiotensin Convertase Enzyme (ACE) Activity and Expression May Contribute to Shorter Event Free Period After Coronary Artery Bypass Graft Surgery. In: Cardiovascular Therapeutics. 2012 ; Vol. 30, No. 3. pp. 136-144.
@article{d52e99b546954759b9a66a14facef8fc,
title = "Differences in Angiotensin Convertase Enzyme (ACE) Activity and Expression May Contribute to Shorter Event Free Period After Coronary Artery Bypass Graft Surgery",
abstract = "Aims: The goal of this study was to investigate the importance of the vascular angiotensin convertase enzyme (ACE) in coronary artery bypass graft surgery (CABG) patients. Methods: Vascular tissue (distal saphenous vein [n= 163] and/or radial artery [n= 120] segments) and blood samples were collected from CABG patients (n= 81). We studied (i) the potency of angiotensin I (AngI) and angiotensin II (AngII) to evoke vascular contractions; (ii) vascular and plasma ACE concentrations; and (iii) ACE genotype of the patients enrolled. Results: The ratio of the potencies (EC 50) of AngII and AngI was significantly lower in radial artery compared to the saphenous vein (0.17 ± 0.03 nM and 0.51 ± 0.14 nM, respectively, P= 0.003), suggesting a 3-fold more effective AngI conversion in saphenous vein samples. Angiotensin constrictions were inhibited with telmisartan and captopril in both saphenous veins and radial arteries. Vascular ACE expression was significantly higher in saphenous vein compared to radial artery (9.7 ± 1.0 ng/mg and 5.3 ± 0.7 ng/mg, respectively, P= 0.01). Serum but no tissue ACE concentration was determined by ACE insertion/deletion polymorphism. Accordingly, no relation was found between serum and tissue ACE expression. Conclusion: ACE-inhibitor therapy targeting tissue located ACE may be beneficial to patients with saphenous vein grafts after CABG surgery.",
keywords = "Angiotensin convertase enzyme, Interventional cardiology, Ischemic heart disease, Saphenous vein graft, Vascular biology",
author = "Andrea Darag{\'o} and Mikl{\'o}s Fagyas and Siket, {Ivetta M.} and Andrea Facsk{\'o} and Zita Megyesi and Judit Kal{\'a}sz and Zolt{\'a}n Galajda and Tam{\'a}s Szerafin and J. H{\'a}rsfalvi and I. {\'E}des and Z. Papp and Attila T{\'o}th and J{\'o}zsef Szentmikl{\'o}si",
year = "2012",
month = "6",
doi = "10.1111/j.1755-5922.2010.00252.x",
language = "English",
volume = "30",
pages = "136--144",
journal = "Cardiovascular Therapeutics",
issn = "1755-5914",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Differences in Angiotensin Convertase Enzyme (ACE) Activity and Expression May Contribute to Shorter Event Free Period After Coronary Artery Bypass Graft Surgery

AU - Daragó, Andrea

AU - Fagyas, Miklós

AU - Siket, Ivetta M.

AU - Facskó, Andrea

AU - Megyesi, Zita

AU - Kalász, Judit

AU - Galajda, Zoltán

AU - Szerafin, Tamás

AU - Hársfalvi, J.

AU - Édes, I.

AU - Papp, Z.

AU - Tóth, Attila

AU - Szentmiklósi, József

PY - 2012/6

Y1 - 2012/6

N2 - Aims: The goal of this study was to investigate the importance of the vascular angiotensin convertase enzyme (ACE) in coronary artery bypass graft surgery (CABG) patients. Methods: Vascular tissue (distal saphenous vein [n= 163] and/or radial artery [n= 120] segments) and blood samples were collected from CABG patients (n= 81). We studied (i) the potency of angiotensin I (AngI) and angiotensin II (AngII) to evoke vascular contractions; (ii) vascular and plasma ACE concentrations; and (iii) ACE genotype of the patients enrolled. Results: The ratio of the potencies (EC 50) of AngII and AngI was significantly lower in radial artery compared to the saphenous vein (0.17 ± 0.03 nM and 0.51 ± 0.14 nM, respectively, P= 0.003), suggesting a 3-fold more effective AngI conversion in saphenous vein samples. Angiotensin constrictions were inhibited with telmisartan and captopril in both saphenous veins and radial arteries. Vascular ACE expression was significantly higher in saphenous vein compared to radial artery (9.7 ± 1.0 ng/mg and 5.3 ± 0.7 ng/mg, respectively, P= 0.01). Serum but no tissue ACE concentration was determined by ACE insertion/deletion polymorphism. Accordingly, no relation was found between serum and tissue ACE expression. Conclusion: ACE-inhibitor therapy targeting tissue located ACE may be beneficial to patients with saphenous vein grafts after CABG surgery.

AB - Aims: The goal of this study was to investigate the importance of the vascular angiotensin convertase enzyme (ACE) in coronary artery bypass graft surgery (CABG) patients. Methods: Vascular tissue (distal saphenous vein [n= 163] and/or radial artery [n= 120] segments) and blood samples were collected from CABG patients (n= 81). We studied (i) the potency of angiotensin I (AngI) and angiotensin II (AngII) to evoke vascular contractions; (ii) vascular and plasma ACE concentrations; and (iii) ACE genotype of the patients enrolled. Results: The ratio of the potencies (EC 50) of AngII and AngI was significantly lower in radial artery compared to the saphenous vein (0.17 ± 0.03 nM and 0.51 ± 0.14 nM, respectively, P= 0.003), suggesting a 3-fold more effective AngI conversion in saphenous vein samples. Angiotensin constrictions were inhibited with telmisartan and captopril in both saphenous veins and radial arteries. Vascular ACE expression was significantly higher in saphenous vein compared to radial artery (9.7 ± 1.0 ng/mg and 5.3 ± 0.7 ng/mg, respectively, P= 0.01). Serum but no tissue ACE concentration was determined by ACE insertion/deletion polymorphism. Accordingly, no relation was found between serum and tissue ACE expression. Conclusion: ACE-inhibitor therapy targeting tissue located ACE may be beneficial to patients with saphenous vein grafts after CABG surgery.

KW - Angiotensin convertase enzyme

KW - Interventional cardiology

KW - Ischemic heart disease

KW - Saphenous vein graft

KW - Vascular biology

UR - http://www.scopus.com/inward/record.url?scp=84860630980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860630980&partnerID=8YFLogxK

U2 - 10.1111/j.1755-5922.2010.00252.x

DO - 10.1111/j.1755-5922.2010.00252.x

M3 - Article

C2 - 21106034

AN - SCOPUS:84860630980

VL - 30

SP - 136

EP - 144

JO - Cardiovascular Therapeutics

JF - Cardiovascular Therapeutics

SN - 1755-5914

IS - 3

ER -